Why a onetime biotech IPO hopeful shifted to a 'blank check' deal
November 08, 2021 at 18:02 PM EST
The company's lead drug targets a deadly lung-scarring disease and could start a mid-stage clinical trial in the first half of next year.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|